bronchodilator, with the largest improvements noted in those with bronchopulmonary dysplasia, who had greater deficits of %FEV 1 when compared with preterm and term controls. One long-term study investigated a 2-week terbutaline administration, but the initial FEV 1 after a single dose did not show a change in %FEV 1 of ≥ 15%, but 5/29 (17%) children had an increased %FEV 1 of ≥ 10%. Conclusions: In this systematic review, disparate studies were identified. Although single doses of bronchodilators appear to improve the FEV 1 in the short term, further studies are required to assess their longer-term benefits not only on airway obstruction, but also their effect on respiratory symptoms.
ences were reduced by 14-17 years [3] . In our previous systematic review and meta-analysis, we reported that preterm-born participants with and without bronchopulmonary dysplasia (BPD) have deficits in percentage predicted forced expiratory volume in 1 s (%FEV 1 ) [1] . The mean differences for %FEV 1 compared with term-born controls were -7.2% (95% CI -8.7 to -5.6%) for the preterm-born group without BPD and -18.9% (-21.1 to -16.7%) for the preterm-born group with BPD. These children may also have increased respiratory symptoms [4] .
The EpiCure study of 11-year-old children born at ≤ 25 weeks' gestation observed that 56% of survivors had an abnormal spirometry and 27% had positive bronchodilator responses, but <50% had received any bronchodilator therapy over the previous year [5] . We reported significant reversible exercise-induced bronchoconstriction in 8-to 12-year-old children who had had BPD in infancy, but only 10% of the preterm-born children with BPD and 12% of the preterm-born without BPD were receiving bronchodilator treatment [6] . It is clear that we need to establish whether preterm-born children and adults need long-term monitoring and treatment, e.g. with bronchodilator treatment, and whether earlier treatment with bronchodilators improves the respiratory symptoms and long-term outcomes of preterm-born children. Currently it is unclear how to optimally manage preterm-born children with respiratory symptoms and airway obstruction.
To the best of our knowledge, there has not been a systematic review of studies that examined whether the deficits for %FEV 1 in preterm-born participants with and without BPD are reversible with bronchodilator treatment. We therefore systematically reviewed the evidence in preterm-born children and adults.
Materials and Methods
We adapted the search strategy used in our previous systematic review on %FEV 1 and preterm birth [1] to include additional key words relating to bronchodilator drug responsiveness (more information on additional key words is given in the online suppl. data; for all online suppl. material, see www.karger.com/ doi/10.1159/000371539). The original search strategy is given in appendix 1 (online suppl. data), and the original data collection form is also given in appendix 2 (online suppl. data). Eight databases and 3 charity websites were searched (see online suppl. data) in May 2013. Ethical approval was not required.
Eligibility Criteria
Studies on bronchodilator responsiveness in preterm-born children or adults with or without BPD were included. 'Preterm' was defined as being born at <37 weeks' gestation, and 'term' was birth at ≥ 37 weeks' gestation. BPD was defined as either the dependence on supplementary oxygen at 28 days of life or dependence on supplementary oxygen at 36 weeks postmenstrual age. Papers not mentioning the response to bronchodilators were excluded. Only studies reporting a change in %FEV 1 in response to bronchodilators were included, hence they were limited to participants ≥ 5 years of age. Studies in all languages from all countries were considered.
Study Selection
The initial search [1] from May 2010 to October 2011 was adapted in May 2013 to include the additional key words relating to bronchodilator drug responsiveness (more information on additional key words is given in the online suppl. data). The original search strategy is given in appendix 1 (online suppl. data), and the original data collection form is given in appendix 2 (online suppl. data). All additional included studies were reviewed by 2 reviewers (M.O.E. and S.J.K.).
Data Collection Process
Data extraction of all studies was performed by 2 reviewers (S.J.K. and M.O.E.). Multiple articles from the same cohort were reviewed, and the article reporting the most complete data was included in the analysis.
Assessing the Quality of the Study and Risk of Bias
A pro forma analysis modified from the Newcastle Ottawa criteria and the Cochrane risk of bias tool assessed the quality of the studies included (more information is given in the online suppl. data, and the data collection form is given in the online suppl. appendix 2). The minimum score was 6 and the maximum 20.
Outcome Measures
We measured the change in %FEV 1 in response to bronchodilator treatment in preterm-born participants.
Analysis of Results
A formal meta-analysis for a change in %FEV 1 after using a bronchodilator was not possible due to the considerable heterogeneity of the disparate studies, hence the results are descriptive.
Results

Studies Selected and Their Characteristics
The initial searches identified 8,839 titles and abstracts, of which 20 studies met the inclusion criteria; when the searches were adapted, we identified a further 2 studies. Twenty-two studies were included . Demographic details are shown in tables 1 and 2 , and further details are given in the online supplementary tables E1 and E2. Twenty-one papers reported a change in %FEV 1 after a single bronchodilator dose, including 3 that administered a single dose of a bronchodilator after exercise [6, 13, 24] . Only 1 study assessed the effect of longer-term (2 weeks) administration of an inhaled β 2 -agonist [7] .
The mean ages of participants in the 22 studies ranged from 5.7 to 20.2 years, including 2 studies of young adults [18, 21] . Participants included were born between 1964 and 2001 and between 24 and 36 weeks' gestation with birth weights ranging from 570 to 2,480 g. The majority of studies included participants born at <32 weeks' gestation or verylow-birth-weight infants. Rates of ventilation and surfactant administration varied widely. Bronchodilator administration was often part of studies investigating lung function.
Of the 21 studies assessing response to a single dose of bronchodilator:
• 16 (76.2%) administered salbutamol (also known as albuterol) • 2 (9.5%) administered isoproterenol • 1 (4.8%) administered terbutaline • 2 (9.5%) did not report the type of bronchodilator administered The majority of studies (14; 66.7%) included pretermborn participants with and without BPD, 4 (19.0%) studies included only preterm-born participants with BPD, and 3 (14.3%) included only preterm-born participants without BPD. Some studies included term-born controls.
Risk of Bias across Studies
Overall, the studies were of moderate quality, with scores ranging from 8 to 19 and a mean score of 13.5 (online suppl. Nixon et al. [13] , USA A subsample of children (n = 53) underwent maximal progressive exercise testing on a cycle ergometer. Spirometry was carried out immediately and 5 min after exercise as well as 20 min after 3 puffs of albuterol delivered via a spacer Moderate-to-severe-BPD group: mean 107.9, SD 9.6 Only 1 control subject and 3 participants with BPD had a ≥12% response to salbutamol (non-significant)
Northway et al. [21] , USA Study participants who had an FEV 1 of <80% were given 3.75 mg of aerosolized isoproterenol at a dilution of 1:400, and flow-volume curves were determined again. The diagnosis of reactive airway disease was based on an increase of >10% in FEV 1 after inhalation of isoproterenol 4 children with BPD had an increase of 10-15% in FEV 1 after isoproterenol, 3 had increases of 15-20% and 4 had increases of >20% Jacob et al. [22] , Canada
After baseline spirometry, spirometry was repeated 15 min after albuterol (nebulized dose of albuterol 2.5 mg in 2.5 ml)
8/14 children in each group showed a significant response to the bronchodilator with an increase in FEV 1 of ≥12% or an increase in FEF of ≥25%
Pianosi and Fisk [23] , Canada Preterm group only: after baseline spirometry, spirometry was repeated after inhalation of 200 μg of albuterol from a metered-dose inhaler with a spacer in order to determine bronchodilator responsiveness defined as a >10% increase in FEV 1 or a 25% increase in FEF 7 children (3 with high-frequency ventilation) had significant improvement in spirometry following bronchodilator administration 
Study Outcomes
The data are presented in tables 1 and 2 and in the online supplementary tables E1 and E2. Due to the heterogeneity of the studies, we were unable to conduct a formal meta-analysis. The heterogeneity was due to:
• Range of bronchodilators used • Variable dosage method, timing and frequency of administration • Different criteria used to assess drug response
In addition, some of the papers commented on the proportion of preterm-born participants with a percentage change in %FEV 1 above varying nominal threshold values that varied. The numerical values were presented in some studies as means and in others as medians, which leads to further difficulty in comparing the studies directly.
Twenty-one papers reported spirometry after a single dose of a bronchodilator [5, 6, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . Sixteen studies administered salbutamol, with doses ranging from 100 μg by meter-dosed inhalers to 5 mg by nebulization [5, 6, 8-13, 16, 17, 20, 22-26] : • 3/16 studies administered salbutamol after exercise; doses were 180 μg [24] , 4 × 100 μg [7] , and 1 study gave 3 puffs without stating the dosage [13] . Of the studies administering bronchodilators after exercise, 2 reported improvement in %FEV 1 after salbutamol [6, 13] , and in the third study, bronchodilator responsiveness was defined as an increase in forced vital capacity (FVC) of ≥ 15%, FEV 1 of ≥ 15% or in midexpiratory flow at 75-25% of forced vital capacity (FEF ) of ≥ 20% and was observed in 47% of the preterm-born participants with BPD and 25% without BPD [24] • 7/16 studies reported the mean change in %FEV 1 [21] . In the former case, 12/17 preterm-born participants with BPD had a positive response defined as a significant increase from baseline of at least 2 indices defined as a change of >10% for the FVC of >20% for the FEV 1 and of >25% for the peak expiratory flow (PEF) rate, FEF 25-75 , FEF 50 and FEF 75 , respectively [19] . In the latter case, 4/26 preterm-born participants with BPD had increases of 10-15% in %FEV 1 after nebulized isoproterenol, 3/26 cases had increases of 15-20%, and 4/26 cases had increases of >20% [21] . One study administered 4 doses of terbutaline at 1-min intervals and reported the median change in %FEV 1 as 13% [15] . Two studies did not report the bronchodilator used [14, 18] . One noted an improvement in %FEV 1 , and, interestingly, in the other study of young adults [18] , the mean change in FEV 1 /FVC after a bronchodilator administration was 6.5% in 7 smokers but only 3.4% in 7 nonsmokers.
Only 1 study assessed the impact of longer-term bronchodilator administration. In that study, the initial response to 0.5 mg of terbutaline did not show a change in %FEV 1 of ≥ 15%, but 5/29 cases (17%) had an increased %FEV 1 of ≥ 10%. Thereafter, data are reported for the PEF during 2 weeks of treatment with terbutaline (0.25 mg twice daily) [7] with twice daily monitoring of PEF at home for 4 weeks to assess diurnal variation. Postbronchodilator PEF increments of ≥ 15% were observed at least 3 times in 31% of patients. Six children had a diurnal variation of ≥ 20% at least 4 times during the 4 weeks of home monitoring.
In summary, the majority of studies reported a deficit in %FEV 1 in preterm-born participants with or without BPD compared with term controls or historical control (reference value) data. The majority of papers reported an improvement in %FEV 1 after bronchodilators. The largest improvements in %FEV 1 were seen in the pretermborn participants with BPD, who had the greatest deficits in %FEV 1 when compared to the preterm-born participants without BPD or the term controls, if studied.
Discussion
We systematically reviewed articles that reported the short-and longer-term effect of bronchodilator administration on %FEV 1 in preterm-born children and adults. The majority reported short-term effects of a single-dose administration with an improvement in %FEV 1 after bronchodilator treatment. We only identified 1 study which investigated longer-term administration (2 weeks) of a β 2 -agonist, although it appears that %FEV 1 results were only reported after the initial dose of terbutaline [7] . The study noted that regardless of BPD, increased bronchial responsiveness was common in preterm-born participants.
Study Limitations
This systematic review has a number of limitations. We were unable to conduct a formal meta-analysis as the publications were disparate. We were limited by the quality and quantity of information presented in the included articles. Overall, the studies were of only moderate methodological quality, and there was a moderate risk of selection bias. The studies are likely to have had recruitment bias, often selecting the worst cases, and were often focussing on areas other than specifically drug intervention. Furthermore, the studies were conducted over a number of years during which much progress in neonatal medicine occurred. We were also limited by the duration of the treatment and the type of bronchodilator used.
With improvements in the medical management of extremely preterm-born infants, more of them are surviving. As we reported previously, these children are at risk of long-term deficits in %FEV 1 even if they do not have BPD in the early neonatal period [1] . In our previous systematic review and meta-analysis, we reported that preterm-born participants with and without BPD have deficits in %FEV 1 compared with term-born participants [1] . There are also growing numbers of latepreterm-born participants who are at risk of deficits in lung function. We reported that these children have deficits in lung function at 8-9 years of age which is similar to the deficits seen in the very preterm children, although these deficits appeared to improve when spirometry was repeated at 14-17 years of age [3] . Although we identified deficits in FEV 1 , it is unclear if these deficits are reversible.
It is possible that deficits in lung function of this magnitude lead to respiratory symptoms. Preterm-born children with and without BPD may experience increased respiratory symptoms, often reported as asthma, which is usually non-atopic; they have increased reported inhaled drug use and increased health utilization, including hospitaliation, especially in early childhood [27] . Preterm-born participants with BPD may also have increased exercise-induced bronchoconstriction and, importantly, may have reversible bronchoconstriction, as recently reported when they were studied at 8-12 years of age [6] .
There is a paucity of data on the impact of longer-term administration of bronchodilators on the lung function of preterm children and therefore a lack of data upon which to make informed decisions and to guide treatment for the survivors of prematurity. It may be that a better understanding of the underlying mechanisms may aid better targeted therapy especially for those with significant airway obstruction. The underlying mechanisms of airway obstruction are likely to be either inflammatory, as suggested by a single study reporting neutrophilic airway inflammation [28] and increased oxidant stress assessed by measuring 8-isoprostane concentration in exhaled breath condensate [29] , or due to smooth muscle hypertrophy, as suggested by pathological studies of preterm infants dying from respiratory failure. There is a clear need to understand the underlying mechanisms before progressing to trials to assess the role of bronchodilators or anti-inflammatory treatments in this group of vulnerable children. Although bronchodilator treatment appears, in the majority of single dose studies, to improve deficits in %FEV 1 , there are many reports of pretermborn children being undertreated with bronchodilators. There may be a tendency to regard respiratory symptoms in preterm-born children as an inevitable consequence of airway injury and remodelling. There is a need to increase awareness of the potential for reversible airway obstruction and to understand the effects of treatment on symptoms and long-term respiratory outcomes in this patient population.
In conclusion, in this systematic review we have identified a number of small disparate studies that suggest a short-term benefit of bronchodilator treatment on FEV 1 in preterm-born participants. However, there is a paucity of data on the effect of longer-term administration of bronchodilators on the lung function of preterm-born children. We would suggest that, on the current low level of evidence of the short-term benefits of bronchodilator treatment on FEV 1 , it would be reasonable to treat deficits in FEV 1 in symptomatic pretermborn participants with bronchodilators with a view to assessing clinical and/or physiological improvements. However, there is an urgent need to not only understand the underlying mechanisms, but also for an adequately powered study to determine whether the use of regular bronchodilators improves existing deficits in lung function and/or respiratory symptoms in pretermborn survivors.
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